Nov 21, 2025 1:26 PM Eastern Standard Time Deadline Approaching: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith Share BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 16, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Perrigo Company plc ("Perrigo†or the "Company†) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclus ...

Core Points - The article highlights the upcoming January 5, 2026 deadline for investors to file a lead plaintiff motion in a class action lawsuit related to Six Flags Entertainment Corporation [1] Group 1 - The class action is on behalf of investors who purchased or acquired Six Flags common stock linked to the company's registration statement and prospectus [1] - The lawsuit is connected to the merger of Six Flags with Cedar Fair, L.P. that took place on July 1, 2024 [1]

Core Points - Rosen Law Firm is reminding purchasers or sellers of Cepton, Inc. common stock during the Class Period from July 29, 2024, to January 6, 2025, about the December 8, 2025, lead plaintiff deadline [1] - Investors who participated in the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Legal Action Details - A class action lawsuit has been filed against Cepton, Inc. for making materially false and misleading statements regarding its business and operations during the Class Period [5] - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5] Next Steps for Investors - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7]

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. by Berger Montague on behalf of investors who acquired KBR shares between May 6, 2025, and June 19, 2025, alleging that the company misled investors regarding a contract with the U.S. Department of Defense's Transportation Command [1][3]. Group 1: Lawsuit Details - The lawsuit claims that KBR misrepresented its relationship with TRANSCOM and the status of a Global Household Goods Contract, despite TRANSCOM expressing serious concerns [3]. - On June 19, 2025, it was revealed that TRANSCOM was terminating the contract, leading to a significant drop in KBR's share price by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 2: Investor Information - Investors who purchased KBR securities during the class period have until November 18, 2025, to seek appointment as lead plaintiff representatives [2].

Core Points - RCI Hospitality Holdings is facing a class action lawsuit for investors who acquired its securities between December 15, 2021, and September 16, 2025 [1] - The deadline for investors to seek lead plaintiff appointment in this class action is November 20, 2025 [1] Company Summary - RCI Hospitality Holdings is identified as the company involved in the class action lawsuit [1] - The lawsuit pertains to securities acquired during a specified class period, indicating potential legal and financial implications for the company [1]

Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business and clinical trials, particularly related to the briquilimab drug product [3]. Group 1: Company Developments - On July 7, 2025, Jasper announced issues with a drug product lot used in its BEACON Study for Chronic Spontaneous Urticaria, leading to a significant stock price drop of $3.73, or 55.1%, closing at $3.04 per share [2]. - The company is halting the development of briquilimab for asthma and SCID, and is implementing cost-cutting measures, including potential restructuring, to extend its financial runway [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Jasper's management made materially false and misleading statements and failed to disclose critical information about the company's operational controls and the risks associated with its clinical trials [3]. - Specific allegations include the lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the company's regulatory and commercial prospects [3]. Group 3: Legal Actions - Investors who purchased Jasper securities during the class period from November 30, 2023, to July 3, 2025, have until November 18, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - UroGen Pharma Ltd. faces a class action lawsuit following significant stock price declines due to the FDA's negative assessment of its drug application for UGN-102, which raised concerns about the drug's efficacy and study design [2][3][4]. Group 1: Company Overview - UroGen Pharma Ltd. is involved in the development of UGN-102, a drug intended for treating recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer [3]. - The company submitted a new drug application (NDA) for UGN-102, which was met with skepticism from the FDA regarding the sufficiency of the submitted data [2]. Group 2: FDA Findings - The FDA's briefing document indicated doubts about the effectiveness of UGN-102, citing the lack of a concurrent control arm in the ENVISION trial, making the primary endpoints difficult to interpret [2]. - The FDA had previously recommended a randomized trial design to UroGen but the company opted not to follow this guidance [2]. Group 3: Stock Price Impact - Following the FDA's briefing document release on May 16, 2025, UroGen's stock price dropped by $2.54, or 25.8%, closing at $7.31 per share [2]. - After the Oncologic Drugs Advisory Committee voted against the NDA on May 21, 2025, the stock fell further by $3.37, or 44.7%, closing at $4.17 per share [3]. Group 4: Lawsuit Details - The class action lawsuit alleges that UroGen made materially false and misleading statements regarding the effectiveness of UGN-102 and failed to disclose significant risks associated with the drug's approval process [4]. - Specific allegations include the inadequacy of the ENVISION clinical study design and the company's disregard for FDA recommendations, leading to a substantial risk of NDA rejection [4].